LCMV gp33-41 TFA是一种来源于淋巴细胞性脉络丛脑膜炎病毒（LCMV）糖蛋白GP1的9肽CTL表位，LCMV gp33-41 TFA可通过H-2Db限制性呈递激活特异性CD8⁺细胞毒性T细胞来介导抗病毒细胞免疫应答。
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
LCMV gp33-41 TFA is a 9-amino acid cytotoxic T lymphocyte (CTL) epitope derived from the glycoprotein GP1 of the Lymphocytic Choriomeningitis Virus (LCMV). LCMV gp33-41 TFA mediates antiviral cellular immune responses by activating specific CD8⁺ cytotoxic T cells through H-2Db-restricted antigen presentation[1-2]. LCMV gp33-41 TFA can be utilized in research related to virus-specific T cell detection, investigation of immunological memory mechanisms, and the development of antiviral immunotherapy platforms[3-4].
In vitro, TCR-transgenic splenocytes were treated with LCMV gp33-41 TFA (5µM) for 2 hours, followed by stimulation with IL-2-containing medium for 5 days. LCMV gp33-41 TFA successfully induced and expanded activated GP33-specific CD8⁺ T effector cells[5]. Bone marrow-derived macrophages (BMDMs) were pulsed overnight with LCMV gp33-41 TFA (10ng/µL) and LPS (100ng/mL), and subsequently co-cultured with P14 CD8⁺ T cells specific for this antigen for 3 days. LCMV gp33-41 TFA induced the expression of the activation marker CD44 on T cells[6].
In vivo, bone marrow-derived dendritic cells (BMDCs) were pulsed with the LCMV gp33-41 TFA (1µM) for 1 hour. Subsequently, 100 to 1×10⁶ of these DCs were adoptively transferred into C57BL/6 mice via intravenous, subcutaneous, or direct intrasplenic injection. LCMV gp33-41 TFA efficiently induced a virus-specific cytotoxic T lymphocyte (CTL) response, conferring rapid and long-term protection against LCMV challenge to the mice. LCMV gp33-41 TFA also enabled the clearance of the virus from peripheral tissues (such as the ovaries and brain), thereby preventing lethal choriomeningitis[7]. The LCMV gp33-41 TFA (100µg) emulsified in complete Freund's adjuvant was used to subcutaneously prime C57BL/6 mice on day 0, followed by booster immunizations with the same dose of peptide emulsified in incomplete Freund's adjuvant on days 7 and 14. LCMV gp33-41 TFA induced only a low frequency of specific CD8 T cells in mice. The majority of these cells exhibited an effector-like phenotype (CD127⁻CD62L⁻) and expressed the inhibitory receptor PD-1[8].
References:
[1] Smyth M, Khamina K, Popa A, et al. Characterization of CD8 T Cell-Mediated Mutations in the Immunodominant Epitope GP33-41 of Lymphocytic Choriomeningitis Virus. Front Immunol. 2021 Jun 14;12:638485.
[2] Gairin JE, Mazarguil H, Hudrisier D, et al. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol. 1995 Apr;69(4):2297-305.
[3] Fridkis-Hareli M, Reinherz EL. New approaches to eliciting protective immunity through T cell repertoire manipulation: the concept of thymic vaccination. Med Immunol. 2004 Dec 8;3(1):2.
[4] Gallimore A, Glithero A, Godkin A, et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes. J Exp Med. 1998 May 4;187(9):1383-93.
[5] Laidlaw BJ, Decman V, Ali MA, et al. Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity. PLoS Pathog. 2013 Mar;9(3):e1003207.
[6] Hering M, Madi A, Sandhoff R, et al. Sphinganine recruits TLR4 adaptors in macrophages and promotes inflammation in murine models of sepsis and melanoma. Nat Commun. 2024 Jul 18;15(1):6067.
[7] Ludewig B, Ehl S, Karrer U, et al. Dendritic cells efficiently induce protective antiviral immunity. J Virol. 1998 May;72(5):3812-8.
[8] Liu Y, Xu L, Jiang Y, et al. Phenotypic and functional analysis of LCMV gp33-41 TFA-specific CD8 T cells elicited by multiple peptide immunization in mice revealed the up-regulation of PD-1 expression on antigen-specific CD8 T cells. Cell Mol Immunol. 2007 Dec;4(6):431-7.
LCMV gp33-41 TFA是一种来源于淋巴细胞性脉络丛脑膜炎病毒（LCMV）糖蛋白GP1的9肽CTL表位，LCMV gp33-41 TFA可通过H-2Db限制性呈递激活特异性CD8⁺细胞毒性T细胞来介导抗病毒细胞免疫应答[1-2]。LCMV gp33-41 TFA可用于病毒特异性T细胞检测、免疫记忆机制研究和抗病毒免疫治疗平台开发的相关研究[3-4]。
在体外，LCMV gp33-41 TFA（5μM）处理TCR转基因脾细胞2小时，随后使用含有IL-2培养基刺激细胞5天。LCMV gp33-41 TFA成功诱导并扩增出活化的GP33特异性CD8+ T效应细胞[5]。LCMV gp33-41 TFA（10ng/μL）与LPS（100ng/mL）脉冲处理骨髓来源巨噬细胞（BMDM）过夜，随后与能特异性识别该抗原的P14 CD8+ T细胞共培养3天。LCMV gp33-41 TFA可诱导T细胞上激活标志物CD44的表达[6]。
在体内，LCMV gp33-41 TFA（1μM）脉冲负载骨髓来源的树突状细胞（BMDC）1小时，随后通过静脉注射、皮下注射或直接脾内注射，将100至1×10⁶个该DC过继转移给C57BL/6小鼠。该处理能高效诱导病毒特异性细胞毒性T淋巴细胞（CTL）反应，使小鼠获得针对淋巴细胞脉络丛脑膜炎病毒（LCMV）攻击的快速、长期保护，并能清除外周组织（如卵巢和大脑）中的病毒，从而避免致死性脉络丛脑膜炎[7]。LCMV gp33-41 TFA（100μg）在完全弗氏佐剂中乳化后，于第0天对C57BL/6小鼠进行皮下注射初次免疫，并在第7天和第14天用不完全弗氏佐剂乳化相同剂量的肽段进行加强免疫。LCMV gp33-41 TFA在小鼠体内仅诱导出低频率的特异性CD8 T细胞，其中大部分细胞呈现效应样表型（CD127−CD62L−），并表达抑制性受体PD-1[8]。
| Cell experiment [1]: | |
Cell lines | Splenocytes |
Preparation Method | Splenocytes were incubated with 5µM LCMV gp33-41 TFA peptide for two hours. After peptide removal, cells were cultured in IL-2-supplemented media for 5 days to generate effector CD8+ T cells. |
Reaction Conditions | 5µM; initial 2-hour pulse, followed by 5-day culture. |
Applications | LCMV gp33-41 TFA peptide stimulation induced the activation and expansion of antigen-specific CD8+ T cells, as measured by increased expression of activation markers (e.g., CD44) and acquisition of effector function. |
| Animal experiment [2]: | |
Animal models | Female C57BL/6 mice (6-8 weeks old) |
Preparation Method | Mice were immunized by subcutaneous injection of 100μg LCMV gp33-41 TFA emulsified in complete Freund's adjuvant (CFA) into the hind footpads on day 0. This was followed by booster immunizations with 100μg of the LCMV gp33-41 TFA in incomplete Freund's adjuvant (IFA) administered on days 7 and 14. |
Dosage form | 100μg; s.c.; prime on day 0 and boost on days 7 and 14. |
Applications | This prime-boost LCMV gp33-41 TFA elicited a low frequency of LCMV gp33-41 TFA-specific CD8 T cells in mice. The induced T cells predominantly exhibited an effector-like phenotype (CD127⁻CD62L⁻), expressed the inhibitory receptor PD-1 (particularly in the spleen and lymph nodes). |
References: | |
| Cas No. | SDF | ||
| 分子式 | C50H74N11F3015S | 分子量 | 1158.24 |
| 溶解度 | DMSO : 100 mg/mL (86.34 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 863.4 μL | 4.3169 mL | 8.6338 mL |
| 5 mM | 172.7 μL | 863.4 μL | 1.7268 mL |
| 10 mM | 86.3 μL | 431.7 μL | 863.4 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet